Clin Cancer Res 2007, 13: 4345–4354.CrossRefPubMed 13. Bai A, Higham E, Eisen HN, Wittrup KD, Chen J: Rapid tolerization of virus-activated tumour-specific CD8+ T cells in prostate tumours of TRAMP mice. Proc Natl Acad

Sci USA 2008, 105: 13003–8. Epub 2008 Aug 22.CrossRefPubMed 14. Whiteside TL, Parmiani G: Tumour-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol learn more Immunother 1994, 39: 15–21.CrossRefPubMed 15. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients withmetastatic melanoma. Proc Natl Acad Sci USA 2003, 100: 8372–8377.CrossRefPubMed 16. Ribas A, Camacho L, Lopez-Berestein G, et al.: Antitumour activity in melanoma and anti-self responses in phase 1 trial with selleck chemicals llc anti-cytotoxis T lymphocyte associated antigen 4 monoclonal antibody. J Clin Oncol 2005, 23: 8968.CrossRefPubMed 17. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S,

Houghton AN: Agonist anti-GITR antibody enhances vaccine-induced AZD1080 cost CD8(+) T-cell responses and tumour immunity. Cancer Res 2006, 66: 4904–12.CrossRefPubMed 18. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S: Treatment selleck products of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005, 202: 885–91.CrossRefPubMed 19. Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL: Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 2007, 82: 93–105.CrossRefPubMed 20. Hanabuchi S, Watanabe N,

Wang YH, Ito T, Shaw J, Cao W, Qin FX, Liu YJ: Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumour necrosis factor receptor-ligand (GITRL). Blood 2006, 107: 3617–3623.CrossRefPubMed 21. Marshall E: Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 2006, 311: 1688–9.CrossRefPubMed 22. Kim JW, Ferris RL, Whiteside TL: Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res 2005, 11: 7901–7910.CrossRefPubMed 23. Tomson TT, Roden RB, Wu TC: Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 2004, 5: 1247–1261.PubMed 24.